ConductScience.org, home

Paper39384682

In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.

Boattini M and 4 others. Eur J Clin Microbiol Infect Dis, 2024. Cited by 23 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series. Papers, record 39384682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39384682

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.
PubMed
Journal
Eur J Clin Microbiol Infect Dis
PubMed
Year
2024
PubMed
Publication types
Journal Article, Case Reports
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
5.57, provisional
iCite
Revised in PubMed
2025-04-07
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Boattini MMatteo
2Bianco GGabriele
3Comini SSara
4Costa CCristina
5Gaibani PPaolo

Source PubMed

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
Azabicyclo CompoundsMajor topic
beta-Lactamase InhibitorsMajor topic
beta-LactamasesMajor topic
Drug CombinationsMajor topic
Klebsiella InfectionsMajor topic
Klebsiella pneumoniaeMajor topic
Aged
Female
Humans
Male
Middle Aged
Bacterial Proteins
Ceftazidime
Drug Resistance, Multiple, Bacterial
Microbial Sensitivity Tests
Retrospective Studies
Whole Genome Sequencing

Source PubMed

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135,139,426
Outbreak of ceftazidime-avibactam resistant Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in a COVID-19 intensive care unit, Italy: urgent need for updated diagnostic protocols of surveillance cultures.
J Hosp Infect2022https://conductscience.org/library/papers/35139426PubMed
236,968,952Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21).JAC Antimicrob Resist2023https://conductscience.org/library/papers/36968952PubMed
336,716,999Colonization by ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients.Clin Microbiol Infect2023https://conductscience.org/library/papers/36716999PubMed
435,187,577Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study).J Antimicrob Chemother2022https://conductscience.org/library/papers/35187577PubMed
534,066,420Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018.Antibiotics (Basel)2021https://conductscience.org/library/papers/34066420PubMed
630,471,402In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.Int J Antimicrob Agents2019https://conductscience.org/library/papers/30471402PubMed
733,618,353Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.Clin Infect Dis2021https://conductscience.org/library/papers/33618353PubMed
833,915,286Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.Clin Microbiol Infect2021https://conductscience.org/library/papers/33915286PubMed
937,237,722Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study.Antibiotics (Basel)2023https://conductscience.org/library/papers/37237722PubMed
1036,154,170In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/36154170PubMed
1133,895,414Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies.J Glob Antimicrob Resist2021https://conductscience.org/library/papers/33895414PubMed
1231,342,772Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update.Ann Pharmacother2020https://conductscience.org/library/papers/31342772PubMed
1333,558,042Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series.J Infect Chemother2021https://conductscience.org/library/papers/33558042PubMed
1436,414,199
Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
Clin Microbiol Infect2023https://conductscience.org/library/papers/36414199PubMed
1536,655,779Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams.Expert Rev Anti Infect Ther2023https://conductscience.org/library/papers/36655779PubMed
1619,015,357Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.Antimicrob Agents Chemother2009https://conductscience.org/library/papers/19015357PubMed
1737,985,552Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022).Eur J Clin Microbiol Infect Dis2024https://conductscience.org/library/papers/37985552PubMed
1834,462,816In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.Eur J Clin Microbiol Infect Dis2022https://conductscience.org/library/papers/34462816PubMed
1935,416,711Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/35416711PubMed
2031,400,759
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Clin Infect Dis2020https://conductscience.org/library/papers/31400759PubMed

See all 46 references

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
42,967,154Responsible use of new antibiotics for critically ill patients suffering from infections due to carbapenem-resistant organisms-a narrative review for an enablement strategy.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42967154PubMed
42,709,211Caerin 1.1/1.9 Inhibits Growth and Biofilm Formation of Carbapenem-Resistant Klebsiella pneumoniae and Induces Coordinated Transcriptomic Stress Responses.Curr Microbiol2026https://conductscience.org/library/papers/42709211PubMed
42,558,781Emergence of carbapenemase KPC-14 in an Escherichia coli isolate: a case report.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42558781PubMed
42,376,570Genomic characterization of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in bloodstream infections indicates OmpK35 and OmpK36 as pivotal key players in resistance mechanisms.Front Microbiol2026https://conductscience.org/library/papers/42376570PubMed
42,137,798Rapid and high-sensitivity quantitative fluorescent immunoassay for detection of Klebsiella pneumoniae carbapenemase.Front Microbiol2026https://conductscience.org/library/papers/42137798PubMed
41,892,432Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel)2026https://conductscience.org/library/papers/41892432PubMed
41,608,681Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens.Front Microbiol2025https://conductscience.org/library/papers/41608681PubMed
41,436,714Emergence of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae: clinical and genomic insights from consecutive bloodstream infections.Infection2026https://conductscience.org/library/papers/41436714PubMed
41,214,240
In vivo evolution of resistance to novel β-lactam/β-lactamase inhibitor combinations through overproduction of the horizontally acquired extended-spectrum AmpC β-lactamase FOX-14 and porin disruption in Serratia marcescens.
Eur J Clin Microbiol Infect Dis2026https://conductscience.org/library/papers/41214240PubMed
41,105,373Impact of ompK35 and ompK36 downregulation on antibiotic resistance in clinical carbapenem-resistant Klebsiella pneumoniae isolates.Folia Microbiol (Praha)2025https://conductscience.org/library/papers/41105373PubMed
40,926,214Epidemiology, resistance profiles, and risk factors of multidrug- and carbapenem-resistant Serratia marcescens infections: a retrospective study of 242 cases.BMC Infect Dis2025https://conductscience.org/library/papers/40926214PubMed
40,600,143Identification of two KPC variants, KPC-204 and KPC-227, in ST11-K64 Klebsiella pneumoniae during prolonged hospitalization of a single patient.Front Microbiol2025https://conductscience.org/library/papers/40600143PubMed
40,521,716Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023).J Antimicrob Chemother2025https://conductscience.org/library/papers/40521716PubMed
40,251,649Clinical and Microbiological characteristics of patients with ceftazidime/avibactam-resistant Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains.Ann Clin Microbiol Antimicrob2025https://conductscience.org/library/papers/40251649PubMed
39,727,974Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.Curr Issues Mol Biol2024https://conductscience.org/library/papers/39727974PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39384682

GET https://conductscience.org/api/papers/v1/39384682/references?page=2